ArticleMolecular medicine reports2019
Hepatitis B virus infection is not associated with fatty liver disease: Evidence from a cohort study and functional analysis.
Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Fatty Liver and Pancreatic Steatosis in Patients with Chronic Hepatitis B and C and Wilson's Disease.Sisli Etfal Hastanesi tip bulteni · 2026Article
- Emerging roles and therapeutic implications of lipid droplet protein perilipin 2 in liver disease.Genes & diseases · 2026Review
- Article
- Prevalence of nonalcoholic fatty liver disease in patients with hepatitis B: A meta-analysis.World journal of clinical cases · 2024Article
- Review
- Non-Alcoholic Fatty Liver Disease in HIV/HBV Patients - a Metabolic Imbalance Aggravated by Antiretroviral Therapy and Perpetuated by the Hepatokine/Adipokine Axis Breakdown.Frontiers in endocrinology · 2022Review
- Fatty Liver Disease in a Prospective North American Cohort of Adults With Human Immunodeficiency Virus and Hepatitis B Virus Coinfection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion.World journal of gastroenterology · 2021Review
- Methotrexate use does not increase the prevalence of hepatic steatosis: a real-world retrospective nested case-control study.Clinical rheumatology · 2021Article
- Prevalence and Incidence of Non-alcohol Fatty Liver Disease in Chronic Hepatitis B Population in Southeast China: A Community-Based Study.Frontiers in medicine · 2021Article
- Multifaceted Interaction Between Hepatitis B Virus Infection and Lipid Metabolism in Hepatocytes: A Potential Target of Antiviral Therapy for Chronic Hepatitis B.Frontiers in microbiology · 2021Review
- Cellular Mechanisms of Liver Fibrosis.Frontiers in pharmacology · 2021Review
- Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome.World journal of gastroenterology · 2020Article
- Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B.Journal of Korean medical science · 2020Article
- [Characteristics, diagnostic and therapeutic strategies for chronic hepatitis B combined with non-alcoholic fatty liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2020Article
- Relevance of reactive oxygen species in liver disease observed in transgenic mice expressing the hepatitis B virus X protein.Laboratory animal research · 2020Review
- Primary Versus Secondary NAFLD: Perspective on Advanced Fibrosis.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hepatitis B virus (HBV) infection has been reported to be associated with the prevalence of non‑alcoholic fatty liver disease (NAFLD). However, the present study demonstrated that the incidence of fatty liver disease in HBV‑infected subjects (16/152, 10.5%) was not significantly different from in non‑HBV‑infected subjects (292/1,714, 17%), following adjustment for age (odds ratio=0.656; 95% confidence interval=0.379‑1.134; P=0.131). Hepatitis B protein X (HBx) is considered a key regulator in HBV infection and several studies have confirmed that HBx serves a pivotal role in the process of fatty liver disease. In the present study, it was demonstrated that HBx‑expressing cells exhibited increased mitochondrial membrane potential, ATP generation, and endogenous mitochondrial respiration. In addition, higher levels of mitochondrial reactive oxygen species (ROS) were detected in HBx‑expressing cells compared with in control cells. Increased ROS production may contribute to increased lipid droplet formation in HBx‑expressing cells, whereas the removal of ROS with N‑acetylcysteine may decrease the accumulation of lipid droplets in a time‑dependent manner. In conclusion, the present findings indicated that HBV, and perhaps more specifically HBx, was not a protective factor against NAFLD. HBx may function as a risk factor for fatty liver disease, based on the findings of the present functional study; however, further studies are required to clarify the effects of HBx on hepatic steatosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.